Reiss-Clark Cindy
Known title: Senior Vice PresidentCIK: 0001916513
Associated companies
Transaction History
| WST | ▲ Buy | Option Exercise | 246 | $52K | 2/18/2025 | View on chart |
| WST | ▼ Sell | Tax Withholding | 83 | $18K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Grant | 551 | $0 | 2/20/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 1,112 | $193K | 8/22/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 1,588 | $436K | 8/22/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 777 | $287K | 8/22/2023 | View on chart |
| WST | ▼ Sell | Open Market | 3,477 | $1.4M | 8/22/2023 | View on chart |
| WST | ▲ Buy | Grant | 970 | $297K | 2/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.